Skip to content

Clinical evidence-based study on the treatment of ischemic stroke with “YiQIHuoXue,QuFengKaiXuan”

Clinical evidence-based study on the treatment of ischemic stroke with “YiQIHuoXue,QuFengKaiXuan” - Clinical evidence-based study on the treatment of ischemic stroke with “YiQIHuoXue,QuFengKaiXuan”

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070169
Enrollment
Unknown
Registered
2023-04-04
Start date
2023-04-05
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic apoplexy

Interventions

treatment group:The experimental group was treated with basic treatment regimen + Zhulong Huoxuetongyu granules
control group:The control group received baseline treatment plus placebo

Sponsors

Hospital of Traditional Chinese Medicine affiliated to Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Meeting the diagnostic criteria of ischemic stroke/cerebral infarction in Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018; (2) Qi deficiency and blood stasis syndrome type, according to the TCM syndrome differentiation standards in the Clinical Research Guidelines for the Treatment of Apoplexy with New Chinese Medicines (2010 edition). ? Age of onset: 18 years =80 years; ? Neurological function: NIHSS score =36; ? The patient and/or authorized client give informed consent and sign the informed consent.

Exclusion criteria

Exclusion criteria: ? Patients with intravenous thrombolysis and mechanical thrombectomy were excluded ? Severe disability from previous stroke (mRS=3); ? Severe gastrointestinal diseases (such as intestinal adhesion, intestinal obstruction, intestinal tumor, etc.) in the last 3 months or active gastrointestinal bleeding in the last 1 month or need to fast for some reasons; ? Patients with known severe renal impairment (eGFR < 25mL/min/1.73m 2) were either planning or undergoing dialysis; (5) There are blood system diseases or other conditions leading to abnormal coagulation function; ? Pregnant or lactating women; ? Those who are allergic or intolerant to the drug; ? Participating in other clinical trials; ? patients who were deemed unsuitable for inclusion by the investigator; ? People with malignant tumors or other diseases whose life expectancy is less than six months.

Design outcomes

Primary

MeasureTime frame
Improved Rankin scale;NIHSS score;National Institutes of Health Neurological Deficit Score;

Secondary

MeasureTime frame
Inflammatory cells;Inflammatory cells;Gene sequencing;

Countries

China

Contacts

Public ContactYangSijin

Hospital of Traditional Chinese Medicine affiliated to Southwest Medical University

13378250818@163.com18244377809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026